We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for leniolisib (Pharming Australia Pty Ltd)
Active ingredients
leniolisib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 to 11 years
Therapeutic area
Immunology